NDAINTRAVENOUSSOLUTION
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Loss of Exclusivity
LOE Date
Mar 8, 2041
182 months away
Patent Expiry
Mar 8, 2041
Company
B
Baxter
Costa Rica - Cartago